Vanguard disaggregates holdings; reports 0 shares in Biogen (NASDAQ: BIIB)
Rhea-AI Filing Summary
Biogen Inc. — The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting zero shares of Biogen common stock and 0% beneficial ownership following an internal realignment.
The filing states certain Vanguard subsidiaries will report holdings separately under SEC Release No. 34-39538, effective after the January 12, 2026 realignment. The report is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Positive
- None.
Negative
- None.
FAQ
What did The Vanguard Group report for BIIB in Amendment No. 13?
Does Amendment No. 13 change who controls Biogen shares for BIIB?
Why did Vanguard file this Schedule 13G/A amendment for BIIB?
Who signed the BIIB Schedule 13G/A amendment for Vanguard?
Does the amendment identify any third parties with rights to BIIB dividends or proceeds?